Modular Medical, Inc.: Form 10-Q for the period ended Dec 31, 2017
Filed with the SEC on Feb 14, 2018 and accepted by EDGAR at Feb 14, 2018, 12:22 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-10-01 to 2017-12-31 | $0 | us-gaap:Revenues |
| Revenue | 9 months2017-04-01 to 2017-12-31 | $0 | us-gaap:Revenues |
| Research and development | 3 months2017-10-01 to 2017-12-31 | $171.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-04-01 to 2017-12-31 | $258.8k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-10-01 to 2017-12-31 | −$260.9k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-04-01 to 2017-12-31 | −$481.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-10-01 to 2017-12-31 | $800 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-04-01 to 2017-12-31 | $800 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-10-01 to 2017-12-31 | −$258.8k | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-04-01 to 2017-12-31 | −$477.9k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-10-01 to 2017-12-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2017-04-01 to 2017-12-31 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2017-10-01 to 2017-12-31 | 15,983,273 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-04-01 to 2017-12-31 | 12,895,670 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2017-04-01 to 2017-12-31 | −$544.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-04-01 to 2017-12-31 | $13.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2017-04-01 to 2017-12-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-12-31 | $4.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $4.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $4.5m | us-gaap:Assets |
| Total liabilities | At period end2017-12-31 | $32.6k | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $4.5m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2017-12-31 | 15,983,273 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001019056-18-000341. Last ingested by Listed: Nov 10, 2026, 07:32 ET. Listed shows no prices and gives no investment advice.